Stock Track | Capricor Therapeutics Plunges 8.11% in Pre-Market as Investors Take Profits After Positive Trial Results

Stock Track12-04

Capricor Therapeutics (CAPR) saw its shares drop 8.11% in pre-market trading on Thursday, continuing a downward trend after a massive intraday surge the previous day. The stock had skyrocketed by up to 399% during Wednesday's session following the announcement of positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.

The pre-market decline is attributed to profit-taking by investors who capitalized on the stock's substantial gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally.

Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also announced the positive results, further validating the treatment's potential. The stock's volatility highlights the market's reaction to breakthrough clinical results and subsequent profit-taking.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134332836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134332836","market":"hk","top_or_hot":-1,"title":"Stock Track | Capricor Therapeutics Plunges 8.11% in Pre-Market as Investors Take Profits After Positive Trial Results","media":"Stock Track","content":"<p>Capricor Therapeutics (CAPR) saw its shares drop 8.11% in pre-market trading on Thursday, continuing a downward trend after a massive intraday surge the previous day. The stock had skyrocketed by up to 399% during Wednesday's session following the announcement of positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The pre-market decline is attributed to profit-taking by investors who capitalized on the stock's substantial gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally.</p><p>Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also announced the positive results, further validating the treatment's potential. The stock's volatility highlights the market's reaction to breakthrough clinical results and subsequent profit-taking.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Capricor Therapeutics Plunges 8.11% in Pre-Market as Investors Take Profits After Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Capricor Therapeutics Plunges 8.11% in Pre-Market as Investors Take Profits After Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-04 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Capricor Therapeutics (CAPR) saw its shares drop 8.11% in pre-market trading on Thursday, continuing a downward trend after a massive intraday surge the previous day. The stock had skyrocketed by up to 399% during Wednesday's session following the announcement of positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The pre-market decline is attributed to profit-taking by investors who capitalized on the stock's substantial gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally.</p><p>Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also announced the positive results, further validating the treatment's potential. The stock's volatility highlights the market's reaction to breakthrough clinical results and subsequent profit-taking.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPR","symbol_name":"Capricor Therapeutics Inc","start_time":0,"source_url":"","article_id":"1134332836","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134332836","pubTimestamp":1764839190,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Capricor Therapeutics (CAPR) saw its shares drop 8.11% in pre-market trading on Thursday, continuing a downward trend after a massive intraday surge the previous day. The stock had skyrocketed by up...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPR":"Capricor Therapeutics Inc"},"translate_title":"个股追踪|Capricor Therapeutics盘前暴跌8.11%投资者在试验结果积极后获利了结","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1},"content_text":"Capricor Therapeutics (CAPR) saw its shares drop 8.11% in pre-market trading on Thursday, continuing a downward trend after a massive intraday surge the previous day. The stock had skyrocketed by up to 399% during Wednesday's session following the announcement of positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.The pre-market decline is attributed to profit-taking by investors who capitalized on the stock's substantial gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally.Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also announced the positive results, further validating the treatment's potential. The stock's volatility highlights the market's reaction to breakthrough clinical results and subsequent profit-taking.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134332836","isCrawlerRequest":true}